S506
Clinical - Haemotology
ESTRO 2026
was used to analyse Δ FEV1 within the VMAT-TBI and cTBI cohorts respectively, and Mann-Whitney U test was used to compare Δ FEV1 between the cohorts. Results: Thirty-four patients treated with cTBI (2019-2021) and 60 patients treated with VMAT-TBI (2021-2024) were included. For patient and treatment characteristics, see Table 1. The median follow-up time was 29 months (3-78) and the 2-year survival was 80.7%. The mean lung dose was significantly lower in the VMAT treatment plans (median 8.0 Gy, range 7.6-8.4 Gy) compared to the conventional treatment plans (median 10.8 Gy, range 10.7-10.8 Gy) (p<0.001) (Fig.1a). VMAT-TBI treatment plans were more homogenous with a median HI of 91% (73-94%) compared to 70% (49-79%) for the cTBI treatment plans (p<0.001). Accordingly, dose-volume histograms show better dose conformality in the VMAT treatment plans (Fig.1b). No patients experienced grade ≥ 3 radiation pneumonitis or other severe radiation-induced side effects. There was no statistically significant change in FEV1% before and after HSCT within either the VMAT (p=0.26) or the cTBI (p=0.67) group, nor was there a statistically significant difference in Δ FEV1 between the patient cohorts treated with the two treatment techniques (p=0.77).Table 1. Patient and treatment characteristics
Figure 1. Dose-volume histograms of lung dose (a), target coverage (b) Conclusion: VMAT-TBI can reduce doses to the lungs and improve dose homogeneity compared to cTBI. No patients experienced severe radiation pneumonitis. Keywords: Total body irradiation, VMAT, lung side effects
Digital Poster 1620
Definition of CTV Using Ophthalmologic Mapping Prior to Radiotherapy in Conjunctival Lymphomas (CALT): The Ege University Experience Emine Serra Kamer 1 , Mustafa Kayhan Ekinci 1 , Melis Palamar 2 , Fahri Ş ahin 3 , Yavuz Anacak 1 1 Radiation Oncology, Ege University, Izmir, Turkey. 2 Ophthalmology, Ege University, Izmir, Turkey. 3 Haematology, Ege University, Izmir, Turkey
Purpose/Objective: Conjunctival lymphoma (CALT) is a rare subtype of ocular adnexal lymphomas. Ophthalmologic
Made with FlippingBook - Share PDF online